Literature DB >> 19162240

The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells.

Yin-Lin Ge1, Xiao Zhang, Jin-Yu Zhang, Lin Hou, Run-Hua Tian.   

Abstract

This study investigated apoptotic mechanisms of down-expression vascular endothelial growth factor (VEGF) by short interfering RNA (siRNA) in human breast cancer MCF-7 cells. Human breast cancer cells were evaluated for the expression of VEGF and VEGF receptor 2 (VEGFR-2). siRNA targeting VEGF mRNA were chemically synthesized and transfected into cells with Lipofectamine2000. In vitro assessments were then made of the ability of anti-VEGF siRNA to knock down expression of VEGF and the subsequent effect this decreased expression had on breast cancer cell apoptosis. Growth curve construction and nude mice experimentation in vivo were performed to assess the effects of VEGF silencing on tumor growth. Those cells transfected with siRNA targeting VEGF showed a 65% knockdown in VEGF expression and a marked increase in cell apoptosis. The expression of Bcl-2 protein in MCF-7 cells was decreased, the level of Bax protein was kept the same, cytochrome c was released from mitochondria into cytosol, and the cleaved Caspase-3 protein rose after siRNA transfection. The siRNA targeting human VEGF could induce apoptosis in MCF-7 cells and the mechanism of apoptosis is possibly related with changing Bcl-2/Bax expression ratio, releasing cytochrome c from mitochondria into cytosol, and up-regulation of Caspase-3 protein, but also could suppress the growth of breast cancer cells in vivo. VEGF might be a potential therapeutic target for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162240     DOI: 10.1016/j.intimp.2008.11.020

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

1.  Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization.

Authors:  Yureeda Qazi; Brian Stagg; Nirbhai Singh; Swita Singh; Xiaohui Zhang; Ling Luo; Jacquelyn Simonis; Uday B Kompella; Balamurali K Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

2.  Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.

Authors:  Yayun Chi; Sheng Huang; Haojie Peng; Mengying Liu; Jun Zhao; Zhiming Shao; Jiong Wu
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

3.  RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo.

Authors:  Yong-Chao Liu; Wen-Hui Ma; Yin-Lin Ge; Mei-Lan Xue; Zheng Zhang; Jin-Yu Zhang; Lin Hou; Run-Hong Mu
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

4.  The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice.

Authors:  Leilei Liang; Keli Ge; Fengying Zhang; Yinlin Ge
Journal:  Cell Mol Biol Lett       Date:  2018-12-15       Impact factor: 5.787

5.  Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment.

Authors:  Xiangyang Zhang; Bin Qin; Min Wang; Junyi Feng; Chenglin Zhang; Chengshen Zhu; Suqin He; Hao Liu; Yaohe Wang; Saadyah E Averick; Nga T N Vo; Lei Huang; Wentao Liu; Zhimin Wang
Journal:  Int J Nanomedicine       Date:  2022-03-05

Review 6.  Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis.

Authors:  John Paulo Vergara; Danielle Benedict Leoncio Sacdalan; Madelaine Amurao-Amante; Dennis Lee Sacdalan
Journal:  Rare Tumors       Date:  2019-05-14

7.  Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Authors:  Marsha Crochiere; Trinayan Kashyap; Ori Kalid; Sharon Shechter; Boris Klebanov; William Senapedis; Jean-Richard Saint-Martin; Yosef Landesman
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

8.  Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-α.

Authors:  W Sun; W Jelkmann; R Depping
Journal:  Cell Death Dis       Date:  2014-07-10       Impact factor: 8.469

Review 9.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.